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Abstract
Background Patients undergoing in-centre haemodialysis (HD) are particularly exposed to the dire consequences of COVID-
19. The present systematic scoping review aims to identify the extent, range, and nature of articles related to COVID-19 and 
maintenance HD: it reports specifically the prevalence of the COVID-19 pandemic in the HD population, implementation 
of strategies for the prevention, mitigation and containment of the COVID-19 pandemic in HD centres, demographic and 
clinical characteristics, and outcomes of the pediatric and adult HD patients.
Methods A multi-step systematic search of the literature in Pubmed, Scopus, Ovid Medline, Embase and Web of Sci-
ence, published between December 1, 2019, and January 30, 2021 was performed. Two authors separately screened the 
titles and abstracts of the documents and ruled out irrelevant articles. A report of the papers that met inclusion criteria was 
performed; then, a descriptive analysis of the characteristics of the included articles and a narrative synthesis of the results 
were performed.
Results The review process ended with the inclusion of 145 articles. Most of them were based on single-centre experiences, 
which spontaneously developed best practices. Most studies were conducted in high-income countries (69.7%) and a part 
of them (9.6%) were not in English. Prevalence of COVID-19 among dialysis patients accounted for 0%-37.6%. Preventive 
measures were reported in 54% of the included articles, with particular emphasis on education, triage, hygiene, and con-
tainment measures. Patients experienced a heterogeneous spectrum of symptoms that led 35%-88.2% of them to hospital 
admission. Median and mean hospital length of stay ranged from 8 to 28.5 and 16.2 to 22 days, respectively. Admission to 
intensive care units varied widely across studies (from 2.6% to 70.5%) and was  associated with high mortality (42.8%–100%). 
Overall, prognosis was poor in 0%–47% of the hospitalized patients.
Conclusions This systematic scoping review provides an overview of the current knowledge on the impact of COVID-19 
on the frail world of HD patients. Furthermore, it may help to implement the existing strategies of COVID-19 prevention 
and provide a list of unmet needs (safe transport, testing, shelter). Finally, it may be a stimulus for performing systematic 
reviews and meta-analyses which will form the basis for evidence-based guidelines.
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Introduction
Emerging evidence shows that patients with advanced 
chronic kidney disease (CKD) are susceptible to the detri-
mental effects of COVID-19 [1]. Patients on renal replace-
ment therapy, especially haemodialysis (HD) patients, 
convey a higher risk of death compared to the general popu-
lation [2–4]. Although age and the burden of accompanying 
comorbidities are associated with a poor outcome [5], dialy-
sis condition is, per se, an independent factor for death after 
contracting COVID-19 [6]. Chronic maintenance dialysis is 
known to induce an immune system dysfunction that theo-
retically lessens responsiveness to SARS-CoV-2 infection. 
Furthermore, in-centre HD patients are more susceptible to 
COVID-19 because they lack the possibility to shelter at 
home during the outbreak. For their dependency on in-centre 
dialysis treatment, patients need to reach the dialysis unit 
thrice weekly and often travel to and from it with public or 
shared transport. This inevitably increases the risk of SARS-
CoV-2 infection [7].
On this background, the deleterious association between 
COVID-19 and the high mortality rate in dialysis patients 
urged the nephrology community to adopt appropri-
ate infection control measures to prevent viral infection 
spread. These interventions, rapidly implemented into clin-
ical practice, have shaped the local and national guidelines 
to mitigate the risk factors associated with SARS-CoV-2 
infection. However, the lack of international consensus 
guidelines on patient management and aggregate data on 
epidemiology and outcomes of COVID-19 has in part 
limited the effectiveness of these measures. Furthermore, 
the different containment strategies related to structural 
problems of some dialysis units and divergent national 
guidelines had the disadvantage of increasing heterogene-
ity across studies. In order to broaden our understanding of 
the effects of COVID-19 on HD patients and identify gaps 
in the current literature, we conducted a systematic scop-
ing review with the aim of mapping and analyzing actual 
evidence on the prevalence, clinical manifestations and 
outcomes of the pediatric and adult HD patients during 
COVID-19 pandemic. A secondary objective of this scop-
ing review was to help the nephrologist to navigate into 
the vast literature published on the COVID-19 and offer 
the opportunity to focus on knowledge gaps and/or con-
troversial areas that need further investigations. However, 
given the evolving situation of COVID-19 worldwide, this 
review should be considered a “work in progress” project. 
Indeed, the map of the currently available evidence will 
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evolve in parallel with the full understanding of COVID-
19 pathogenesis in the general population as well as in 
patients on maintenance HD.
Methods
Search strategy
This systematic scoping review aimed to furnish an over-
view of the available literature on two research questions:
• Which has been the magnitude of the impact of the 
COVID-19 pandemic on the frail world of the HD 
patients?
• What strategies were implemented in the clinical prac-
tice for the prevention, mitigation and containment of the 
COVID-19 pandemic in HD centres?
To address this broad topic of interest, we followed pub-
lished recommendations of Preferred Reporting Items for 
Systematic Review and Meta-Analysis Protocols (PRISMA-
P) checklist and the PRISMA extension for scoping reviews 
[8, 9]. We also corresponded with experts in the field to 
sharpen search strategy and selection criteria. The review 
was not prospectively registered in any database of literature 
reviews (e.g., PROSPERO) as it was not applicable.
The search strategy was conducted after consultation with 
two librarians (C.P. and G.V) with expertise in the scientific 
literature. A literature search from December 1, 2019 to Jan-
uary 30, 2021 was conducted on the following 5 databases: 
PubMed, OVID Medline, Scopus, Embase, Web of Science 
and Google Scholar. Search in Cochrane Library did not 
furnish any results. The database results were uploaded on 
a reference manager software  (Mendeley®).
We performed a multi-step search strategy (Fig. 1) [10] 
fully reported in the Supplementary Material. After iden-
tification of the literature, all duplicates were removed 
Fig. 1  Preferred reporting items 
for systematic reviews and 
meta-analyses (PRISMA) flow 
diagram of the study
Records identified through database 
searching: 
   EMBASE (n =1606) 
   OVID MEDLINE (n =2067) 
   PUBMED (n =1110) 
   SCOPUS (n =3357) 
   WEB OF SCIENCE (n =551) 
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through other sources
Records removed before 
screening (n=3425) 
Records selected by title and 
abstract (n =5271) 
Records excluded because they 
did not meet the inclusion criteria 
(n =4724) 
Full-text articles assessed for 
eligibility (n =547) 
Records excluded (n =402) 
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automatically. The screening of the articles consisted of 
two stages: eligibility of references according to inclusion 
and exclusion criteria and selection of the articles. Selec-
tion of the articles was independently accomplished by two 
reviewers (G.A and A.F.) after the screening of titles and 
abstracts followed by the retrieval and screening of full-
text articles. Disagreements were resolved through discus-
sion between the two reviewers, or with the help of a third 
reviewer (R.M.), a researcher with 16 years of experience 
in the field of nephrology. Data charting from the selected 
studies included information on authorship, type of study, 
country, study population, modality of COVID-19 diag-
nosis, prevalence of the COVID-19 pandemic in the HD 
population, implementation of strategies for the prevention, 
mitigation and containment of the COVID-19 pandemic in 
HD centres, demographic and clinical characteristics, and 
outcomes of the pediatric and adult HD patients.
Results
Our search retrieved 8696 articles of which 5271 remained 
after the exclusion of duplicates (Fig. 1). After title and 
abstract screening, 4724 articles were further removed. The 
full texts of the remaining 547 articles were screened and 
402 were excluded. The final review comprised 145 articles.
Most articles (69.7%) come from high-income countries 
whereas the remaining articles come from upper-middle-
income (26.6%) and low-middle countries (3.6%) (Fig. 2). 
Six (4.1%) international collaborative studies were con-
ducted in Europe and US. The review included articles that 
were translated into English from French (1), German (1), 
Italian (7), Russian (1) and Spanish (4). The arguments dis-
cussed in the review have been grouped into 4 domains: 
prevalence of the COVID-19 pandemic in the HD popula-
tion, implementation of strategies for the prevention, miti-
gation and containment of the COVID-19 pandemic in HD 
centres, demographic and clinical characteristics, and out-
comes of the COVID-19 HD patients.
Prevalence of the COVID‑19 pandemic in the HD 
population
Prevalence of COVID-19 was reported in 22 (15.1%) stud-
ies, including 7 letters to the editor (31.8%). The population 
screened for COVID-19 consisted of 8338 patients (range 
13–1542). Studies were conducted principally in China 
(31.8%) and Spain (27.2%). As detailed in Table 1S, dif-
ferent screening tests were used to estimate the prevalence 
of COVID-19. The screening was carried out using real-
time polymerase chain reaction (RT-PCR) (45.5%) [11–21], 
serology (27.2%) [18, 20, 22–25], computed tomography 
(CT) scan (confirmed by SARS-CoV-2 RT-PCR) (13.6%) 
Fig. 2  World distribution of articles retrieved for the review (Singapore is not displayed on the world map but contributed with three publica-
tions)
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[26–28] and combination of PCR and serology (13.6%) 
[29–31]. Considering all modalities of testing, prevalence 
of COVID-19 among HD patients ranged between 0 and 
37.6% [11–32]. When COVID-19 was diagnosed by anti-
body testing, prevalence varied from 4.8 to 36.2% [23, 25]. 
A seroconversion of 97.5% was detected in PCR-positive 
patients [23], whereas it occurred in 4.4–19.0% [20, 23] of 
PCR-negative patients. Prevalence of COVID-19 in pediatric 
patients was assessed in only two studies reporting a sero-
prevalence of 23–38% (Fig. 1S) [22, 24]. The results of the 
epidemiology studies highlighted that asymptomatic patients 
accounted for about one-quarter of PCR-based screening of 
HD population (Fig. 2S).
Implementation of strategies for the prevention, 
mitigation and containment of the COVID‑19 
pandemic in HD centres
Surveillance and appropriate management of suspected or 
confirmed COVID-19 patients play a key role in the pre-
vention, mitigation and containment of the COVID-19 pan-
demic in HD centres. Management of in-centre patients was 
reported in 81 (55.8%) publications, including 19 (23.4%) 
research articles. Most of the studies came from US (23.4%) 
followed by China (11.1%) and Italy (11.1%). A minority 
(5.4%) of the articles included an international authorship.
Education and recommendations
Given the evolving situation, continuous education on 
COVID-19 was considered essential for HD patients 
[33–44]. Dialysis staff provided patients with instructions 
(in appropriate languages) [41, 44–48] about respiratory 
hygiene, coughing and sneezing etiquette [39, 43, 45–52], 
how to use the masks [34, 39, 44, 46–48, 52–54] and how to 
practice self-quarantine at home and with family members 
after dialysis [50]. Signed posts or distribution of educa-
tional pamphlets in the patient’s language were also part of 
the educational program on COVID-19 [12, 33, 38, 47, 50, 
55, 56].
Particular emphasis was placed on hand hygiene, mask-
ing and social distancing. Handwashing [29, 33, 34, 40, 43, 
57, 58] with alcohol-based solutions or soap [41, 42, 47, 
51, 54, 56, 58–61] was advocated for patients presenting 
at triage [12, 21, 38, 47, 54, 56, 62–64], prior to departure 
from the dialysis unit [38, 47, 64] and if in contact with res-
piratory secretions [33, 47]. Fistula arm was washed before 
starting dialysis [16, 29, 60]. In the COVID area, patients 
implemented personal protective equipment (PPE) including 
gloves throughout the dialysis session [29, 65–67].
Patients were instructed to wear a surgical mask since 
leaving house [38] until hospital arrival [16, 35, 38, 43, 56, 
63, 66, 68] and also during the ride [49, 54, 55]. To reduce 
the risk of infection within facilities, the use of the mask was 
recommended throughout the dialysis session [35, 36, 44, 
49, 51, 54, 55, 57, 60, 61, 63, 69–73] unless it was made of 
textiles[54] or was worn by someone that was incapacitated 
to remove it without assistance [48]. Conversely, some rec-
ommendations supported the choice to wear a mask accord-
ing to the epidemiology risk in the community principally 
for asymptomatic patients [38].
With regard to family relationships, HD patients needed 
to reduced contact with other people on their non-dialysis 
days [33, 47, 51, 65, 73]. Personal contacts, especially with 
younger relatives [33, 47, 65] were discouraged. A simi-
lar restriction was valid also for public, private or religious 
events or travels [47].
Transport
Use of individual transport to and from dialysis facilities—
instead of public or shared transport—was proposed as a 
measure to prevent diffusion of COVID-19 [29, 33, 39, 40, 
42, 47, 49, 68, 73]. Drivers were instructed to comply with 
infection control measures [29, 33, 38, 42, 57] including 
sanitization of the shuttle bus between rides [29, 33]. Driv-
ers were invited to report any patient with symptoms to the 
dialysis facility and vice versa [33, 44]. Hand sanitizers 
needed to be accessible for patients and drivers on vehicle 
[33] and hand hygiene was required before and after entering 
the vehicle [38].
Public transport for suspected and/or confirmed COVID-
19 patients was forbidden [29, 49–51, 53, 57, 62, 74]. In the 
absence of separate transportation, patients with confirmed 
COVID-19 were gathered in the same vehicle, providing 
them with a mask [38]. A possible solution for a patient 
who could not be provided with a separate transport was 
hospitalization [42].
Structural changes in the dialysis units
Different routes (including lift) for symptomatic and asymp-
tomatic patients were designed to avoid cross-contamination 
among subjects [21, 29, 34, 60, 75].
Dispensers of hydro-alcoholic solutions [39, 41, 47, 50, 
60] were installed in waiting rooms and, more generally, 
in the facility [43, 67]. Availability of tissue paper, masks 
[39, 50], easy access to PPE [33, 74] and a distance of at 
least 1–1.5 [61], 1.8–2 m [36, 48, 76] between patient beds 
needed to be ensured in the dialysis centre.
A separate room was reserved for testing [29, 38, 47, 67, 
74] suspected or confirmed COVID-19 patients [16, 21, 29, 
33, 36–38, 40, 43, 46–48, 50, 52, 56, 57, 62, 68, 77–79]. 
Although it was not a primary prerequisite [38, 46], a nega-
tive air pressure room was preferable for quarantine patients 
[37, 47, 49, 80]. In absence of a separated room, suspected 
 Journal of Nephrology
1 3
or infected patients were courted on a separate shift [38], 
namely, during the last shift of the day, in a corner or at the 
end-of-row station [33, 35, 36, 38, 43, 44, 47, 48, 50, 52, 
53, 72].
Cohorting suspected or confirmed COVID-19 patients 
together with asymptomatic subjects required droplet/con-
tact precautions [38] and the maintenance of a distance 
longer than 1.8 m (6 feet) [44, 50, 52], 2 m [36, 40, 53, 55, 
67] or as far as possible [36]. Another option was maintain-
ing at least 2 m between patients using separating materials 
to provide spatial isolation [37, 38].
Peripheral dialysis centres, without the possibility of 
isolation and care of suspected or confirmed COVID-19 
patients, needed to centralize patients towards referring 
hospitals [60].
Identifying toilet for suspected or infected cases [40], and 
maintaining good air conditioning and ventilation of dialysis 
rooms was suggested as preventive measures [36, 47, 51, 
53, 67, 79].
Functional changes in the routine dialysis care
Patients were assigned to specific dialysis shifts [36, 49, 71] 
and patterns of patient flow were controlled by dialysis staff 
during the shift changes [49, 71]. Screening of the patients 
was required before shifting them to another unit [56].
Patients from different long-term care facilities or from 
other units were not cohorted together unless full droplet/
contact precautions were respected [38]. Cohorting symp-
tomatic patients with probable or suspected COVID-19 was 
forbidden [38, 47].
Among the series of containment measures patients had 
to enter the locker room one by one and left all their clothes 
inside the locker [29] or changing clothes and shoes before 
entry into the dialysis room [61].
Visitors were limited [44] or not allowed in the dialysis 
facilities [12, 21, 33, 39], even though a more permissive 
recommendation allowed the presence of visitors only if they 
facilitated the dialysis treatment of asymptomatic patients 
[38].
Number of dialysis per day was increased to reduce the 
number of patients per shift as well as in the waiting room 
[74]. Frequency of dialysis sessions was not shortened or 
paused to leave unaffected dialysis quality [36]. However, 
in a resource-constrained environment, a strategy could be 
taken into account shortening dialysis treatment time to 3 h 
in all stable patients [29] or reducing a three times weekly 
HD program to twice-weekly dialysis [81]. The latter solu-
tion should be considered provisional and be reserved for 
patients with preserved residual kidney function, mini-
mal inter-dialytic weight gain and without hyperkalaemia 
or severe comorbidities [38]. For new dialysis patients, 
incremental twice-weekly dialysis could be taken into 
account to limit their time in the dialysis units [82].
The frequency of routine bloodwork and access flow 
measurement for stable patients was reduced to no more 
than 6 weeks unless clinically indicated [38]. Teleconsul-
tation was implemented to decrease medical contact with 
patients [83].
Testing for COVID‑19
Dialysis patients should be prioritized to have expeditious 
access to testing for COVID-19 [38]. Criteria for performing 
screening tests varied among studies. Two recommendations 
were released: universal screening for every dialysis patient 
[84] or reserving testing only for symptomatic patients [47, 
48, 56, 85, 86]. However, despite the consistent implemen-
tation of SARS-CoV-2 testing, diagnosis of COVID-19 
remained challenging in some dialysis units [87].
It was recommended to repeat a nasopharyngeal swab 
in case of a negative test for COVID-19 and a high clinical 
suspicion [38, 79, 80]. Infectious disease specialists consul-
tation was required if more than 2 tests for a single patient 
resulted negative [38].
One study reported that CT scan once every 2 weeks was 
considered helpful to recognize and isolate patients as early 
as possible in the incubation period [80]. Conversely, other 
authors asserted that CT scan [38] as well as serology [48, 
68, 79] (in the acute phase) were inappropriate for the diag-
nosis of COVID-19.
Pre‑triage and waiting area
According to staff availability, dialysis staff phoned all 
patients before each dialysis shift to determine whether they 
had COVID-19 symptoms [17, 33, 45, 88]. Another strategy 
consisted of informing the facility of suspicious symptoms 
or contacts with COVID-19 subjects [38, 42–44, 49–53, 55, 
57, 63, 65, 67, 72, 86, 88, 89] or in case of contact with 
COVID-19 patients [70].
Patients and transport companies were advised for pro-
gressive arrival and departure times to avoid overcrowded 
areas [29], and medically stable patients were suggested to 
wait outside the facility or in their vehicles [29, 38, 44, 47, 
48, 52, 67, 90].
If the patients would wait in a communal area, sits 
needed to be separated by at least 1, [72] 1.5 [42, 49, 62] or 
about 2 m (6 feet) apart from each other [29, 33, 38, 42–45, 
47–49].
Patients with confirmed COVID-19 were not allowed to 
wait in the common area [38, 48], unless (for special needs) 
they wore a mask and maintained > 2 m distance from oth-
ers [38].
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Triage
A pre-dialysis triage was based on the assessment of symp-
toms or signs suggestive for COVID-19 [29, 36–38, 41, 
43–45, 47, 48, 50, 51, 58, 62, 66, 72, 79, 80, 86, 89, 91–93].
A questionnaire was provided regarding symptoms, expo-
sure, contact and travel history for all the patients at every 
shift of dialysis [17, 33, 38, 52, 73]. This could be reserved 
even to visitors if they were allowed [38]. Atypical symp-
toms, including change from previous well-being and altered 
neurological status were considered suspect in the elderly 
and immune-compromised patients [38].
Body temperature was measured to all people prior entry 
to the dialysis centre [12, 29, 38, 41, 47, 53, 58, 61, 64, 
66, 68–70, 73, 80, 92–95] using digital [12, 93] or infrared 
thermal devices [88].
An alert temperature was set at ≥ 37 °C [90], 37.3 °C, 
[35, 38, 96] ≥ 37.5 °C [29, 34, 66, 72, 93], 37.8 °C [48, 
90], 38 °C [49, 89, 97] in different studies. A re-check of 
temperature with different types of thermometer was prac-
ticed [93]. After triage, some recommendations suggested 
a double-check of temperature and respiratory symptoms 
in the waiting room [96]. In some places patient’s tempera-
ture measurement was performed before getting into shuttle 
bus headed to HD unit [97] or body temperature check was 
combined with a QRcode (dowloaded on the mobile phone) 
reporting the epidemiological risk of the patient [95].
During the dialysis session
Eating was not allowed during the dialysis session [16, 29, 
36, 39, 66] to minimize time without mask [42, 90]. Special 
indications were released for diabetic patients after testing 
blood glucose [29]. If the patient manifested dyspnoea or any 
other clinical suspicious symptoms (temperature ≥ 37.5 °C) 
[97], HD session had to be stopped and the patient moved to 
a separate area for SARS-CoV-2 screening [16].
Screening and management of patients under investigation
According to local rules, the patients suspected of COVID-
19 were sent to: (1) emergency room; [62, 66, 67] (2) hos-
pital (e.g., COVID-19 referral hospital); [80] (3) dedicated 
isolated area in the dialysis ward [40, 66, 67]; (4) back home 
[62] or postponing HD session till the availability of the 
nasopharyngeal swab result [62, 74]. However, according to 
national recommendation, even asymptomatic patients could 
be hospitalized to control the spread of the infection [53].
From a clinical standpoint, physical examination and 
workup were suggested before dialysis [60, 66, 90]. Beyond 
SARS-CoV-2 PCR nasopharyngeal swab, [16, 62] examina-
tions included lab blood tests, [16] arterial blood gas analy-
sis, oxygen saturation, measurement of body weight, and 
chest X-rays [62]. Assessment of the patient’s fluid status 
was essential to plan the next dialysis session [89].
Patients under investigation with negative tests were de-
escalated back to their dialysis unit unless they remained 
symptomatic. In such patients, the plan was to continue 
cohort dialysis until the second swab came back as nega-
tive [57].
Recommendations for asymptomatic contacts consisted 
of a screening tests for COVID-19 and the referral to the HD 
cohort isolation adopting contact and droplet precautions 
[34, 48, 86]. In this setting, cohort isolation was discontin-
ued after a negative result of nasopharyngeal swab on the 
thirteenth day after contact [34].
Management of the confirmed COVID‑19 HD patients
According to the national guidelines, an outbreak of 
COVID-19 in dialysis units could be notified to the local 
public health department [38, 46, 48]. Confirmed COVID-
19 patients were preferably managed in an outpatient setting 
[49, 74] if they were stable and there was the possibility to 
maintain home isolation and use dedicated transport. This 
strategy allowed to minimize the need for hospitalization 
beds [49].
High-efficiency dialyzers were used since many patients 
were considered in high catabolic states [98]. Heparin-free 
dialysis was avoided to reduce the need for frequent circuit 
flushing [92] and the risk of clotting [42]. One study under-
lined that despite some thromboembolic events (dialyzer 
clotting, arteriovenous fistula thrombosis) dose of heparin 
was not increased for all COVID-19 patients [21].
When the HD patient was admitted to a non-ICU ward, 
portable dialysis machines (including reverse osmosis 
machines) were used to keep COVID-19 patients in their 
rooms [36, 66, 81]. If the patient was being followed-up 
in the ICU, intermittent or continuous renal replacement 
therapy could be performed at the bedside [36]. Dialysis 
machines used for infected patients were generally restricted 
in COVID-19 areas [49, 62, 99].
Discontinuation of isolation
Isolation must have continued until the patient became 
asymptomatic, for a minimum of 14 days and until 2 nega-
tive tests were separated by at least 24 h [38, 42]. Another 
recommendation reported that asymptomatic patients could 
only be de-isolated after two consecutively negative results 
with a 24- [34, 58, 62, 80] or 48-h [42] interval regardless of 
the time elapsed from the diagnosis. However, if symptoms 
persisted, the patient continued HD treatment in an isolated 
room, even with a twice negative test [34]. Duration of iso-
lation could be longer than 14 days for immune-compro-
mised patients [38, 100]; therefore, a test-based strategy was 
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suggested to avoid the risk of SARS-CoV-2 spreading [86]. 
Consultation with health authorities or local infectious dis-
ease experts on a case-by-case basis was suggested [38, 47].
Surgical operations
Surgical revision of malfunctioning vascular access [101] 
or the placement of vascular access remained an essential 
life-saving procedure [33, 44, 50, 101–104]. A local rule 
supposed to postpone the creation of arteriovenous fistulae 
for patients within six months of requiring HD [57].
Before vascular access surgery, patients underwent 
COVID-19 screening [47, 67, 105]. Operations on patients 
with confirmed or suspected COVID-19 infection were car-
ried out in a designated room [47] if postponing the proce-
dure was not advisable [101].
Disinfection
Dialysis stations and chairs were disinfected per protocol 
(using active product on SARS-CoV-2) [12, 38, 44, 46, 
48–52, 66] including handrails on scales, waiting room 
seats, doorknobs and elevator buttons [46, 74]. Disinfection 
of hospital linens required soap and high temperature [65].
Ventilation [36, 40, 75] and terminal disinfection of 
the room including equipment and supplies was advised 
between two dialysis shifts [35, 38, 67, 75, 78, 94]. One 
percent diluted bleach (sodium hypochlorite) was used for 
floor and surface disinfection and 10% diluted bleach or 70% 
alcohol for areas contaminated with patient secretions [53, 
56, 72, 73, 75]; instead, nebulizing hydrogen peroxide was 
used for room decontamination [12].
Pediatric patients on HD
Four articles reported the recommendations for pediatric 
patients on dialysis. Education about COVID-19 includ-
ing hand, respiratory hygiene and use of PPE was provided 
for patients and caregivers [76, 106, 107]. Caregivers were 
instructed to advise the dialysis unit of Covid-19 symptoms 
before entry [76]. Private transportation [59, 106] or trans-
portation provided by health authorities were suggested 
[106]. Children were accompanied by only one caregiver, 
preferably always the same [76, 106].
It was recommended to wear a mask [59, 76, 106, 107] 
(unless < 2 years old) [48], wash hands with alcohol-based 
hand rub [59, 76, 106] and maintain a social distance 
between other patients of at least 1 m. [59, 76] Screening of 
body temperature [59, 107] and respiratory symptoms[107] 
was required for patients and families before entry into dialy-
sis facilities [76].
Dialysis beds needed to be spaced at a minimum distance 
of 1–2 m apart [76, 106, 107]; if these conditions could 
not be met, curtains were used to separate patients [107]. 
Unnecessary talking or eating was avoided during dialysis 
[106, 107].
Transfer of patients to different dialysis units was reduced 
as a control measure [106].
COVID-19 patients or suspected patients were dialyzed 
in a dedicated room at the last shift or with the same dialysis 
machine [59, 106, 107]. Patients with a COVID-19 positive 
caregiver performed dialysis in an isolated room [76, 107].
For all patients, dialysis was not reduced or shortened 
[59]. Suspected or confirmed COVID-19 patients were trans-
ferred to designated COVID-19 HD units if there was no 
space and/or a dedicated workforce [76].
Disinfection measures were applied between each shift 
using 1% bleach solution or 70% alcohol-based solution 
[76]. The dialysis machine was wiped with 70% ethyl alco-
hol or 0.05% chlorine solution [106].
Perspective
Only one report emphasized the need to construct appropri-
ate numbers of isolation rooms, adequate spacing between 
dialysis beds and space in the waiting room for future dialy-
sis units. [38]
Demographic and clinical characteristics 
of the confirmed COVID‑19 HD patients
Clinical characteristics of in-centre HD patients with 
COVID-19 have been detailed in 57 (39.3%) studies includ-
ing 7376 patients (range 1 to 2336) (Table 2S). The majority 
of studies were conducted in China (21%) followed by Spain 
(14%) and UK (10.5%); 1.7% of the articles included an 
international authorship.
Age of confirmed COVID-19 patients on HD was largely 
heterogeneous since principally tends to reflect national 
policy of access to dialysis treatment. Median and mean 
age of this large cohort of patients ranged between 48 and 
79.5 years [11, 15, 17, 21, 23, 61, 82, 94, 108–122] and 
54.1–76 years, [6, 19, 25, 31, 32, 69, 93, 123–135] respec-
tively. The percentage of male was 37.5%-100% of the exam-
ined population [11, 13, 15, 17, 19, 21, 23, 25, 31, 32, 69, 
82, 94, 108–131, 133–138].
In order to investigate the clinical manifestations of 
COVID-19 in HD patients, we collected information on 
COVID-19-related symptoms. Observation of the data led to 
the conclusion that COVID-19 HD patients showed a wide 
range of symptoms that reflected the pleiotropic manifesta-
tions of the infection. The worsening of symptoms led to the 
hospitalization in 35%-88.2% of cases. The prevalence of 
the main COVID-19-related symptoms is shown in Table 1.
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Shedding
Data on RNA shedding after COVID-19 diagnosis have been 
reported in 6 articles, including one case report. Nasal shed-
ding of SARS-CoV-2 was detected in 41% of patients by 
day 15 following the initial positive swab [100]. On average 
shedding of viral particles lasted 15.1–29 days in infected 
patients on HD [135, 139]. Two studies reported that HD 
patients tested positive for SARS-CoV-2 RNA on repeated 
testing despite being negative on two prior consecutive naso-
pharyngeal swabs [138, 140]. Prolonged viral RNA shedding 
has been reported until 79 days in an adult HD patient [140] 
and 28 days in a pediatric patient [141]. Only one anecdotal 
case of reinfection has been reported in a dialysis patient 
[142].
Diagnosis
In research articles reporting clinical manifestation and 
outcome of COVID-19 patients (78[54.4%]) the diagnosis 
of SARS-CoV-2 infection relied principally on RT-PCR 
(52[63.4%]) [11–20, 32, 61, 62, 69, 93, 94, 100, 108–111, 
113, 115–124, 126, 129, 132, 134, 135, 138–151], serol-
ogy (4[6.3%]) [18, 20, 22–24, 86, 99], RT-PCR and sero-
logical assay (5[6.6%])[29–31, 85, 127, 152] or a combi-
nation of diagnostic tests including clinical evaluation [6, 
13, 19, 21, 112, 114, 125, 128, 130, 131, 133, 136, 137, 
153, 154].
Table 1  Prevalence of COVID-19-related symptoms in HD patients
* Mean weight loss of 2.4 kg [21, 154]
# Imaging abnormalities refer to COVID-19-related lesions
Symptoms/signs Prevalence
Adult population
 Fever 9–100% [6, 11, 13, 15–17, 21, 69, 93, 94, 108–110, 112, 114, 116, 119–125, 127, 130, 
133, 135, 143]
 Cough 7.1–83.9% [6, 13, 15–17, 21, 27, 69, 108–112, 114, 116, 119–125, 130, 132, 133, 135, 
138]
 Myalgia/fatigue 2.9–63% [6, 11, 15, 21, 27, 69, 108, 110–112, 114, 119–125, 130, 132, 135]
 Anorexia 9.3–57% [27, 110, 112, 114, 121]
 Dyspnea/gasping 0–56% [6, 11, 15–17, 21, 27, 69, 93, 108–112, 114, 119–122, 125, 127, 130, 132, 133, 
138]
 Nausea/vomit 4.7–43.6% [6, 13, 69, 110, 112, 121, 122, 143]
 Gastrointestinal/diarrhea 0–40% [6, 11, 15, 16, 21, 69, 93, 108–111, 114, 116, 119–125, 132, 133, 135, 138]
 Expectoration 21.4–33% [69, 121, 132]
 Anosmia/dysgeusia 4–21.6% [113, 116, 133]
 Sore throat 0–20% [6, 11, 16, 17, 21, 27, 69, 108, 111, 112, 114, 132]
 Headache 6.25–8.1% [6, 111, 114, 121]
 Altered mental status 5% [138]
 Ageusia 3–13% [21, 116]
 Chest pain 2.3–6.5% [21, 124]
 Conjunctival congestion 7.6% [109]
 Dizziness 14% [121]
 Rhinorrhea/nasal congestion 0%–14.3% [109, 112, 132]
 Abdominal pain 5.2% [135]
 Ischemic stroke 20% [146]
 Lymphocytopenia 50–100% [15–17, 21, 25, 93, 110, 111, 118, 130]
 Weight loss* 40–100% [21, 143]
 Chest X-ray  abnormalities# 46–81% [6, 11, 108, 123, 129, 135, 136]
 Computed tomography  abnormalities# 27.5–100% [6, 15, 19, 25, 111, 112, 114, 120, 121, 125, 132, 133]
ICU Pediatric population
 Fever, fatigue, poor appetite, headache and lymphope-
nia at lab tests
Chest X-ray negative for COVID-19 lesions
Case-report [141]
 Fever, body aches, cough, fatigue and nasal congestion Case-series (one out of three patients was symptomatic) [149]
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Outcomes of the confirmed COVID‑19 HD patients
Outcome of patients on in-centre HD was evaluated on 52 
(35.9%) articles including 12,365 patients (range 11–3160) 
COVID-19 patients (Table 3S). Studies come principally 
from China (15.3%), Italy (15.3%) and Spain (11.5%); 
3.8% of the studies included European authorship. Table 2 
describes the timing of the main events occurring in the 
COVID-19 HD patients. All outcome measures were influ-
enced by the sample size, the age of patients, length of fol-
low-up and policy of healthcare delivery. Excluding stud-
ies reporting outcome of patient admitted to hospital as a 
preventive measure and regardless of symptoms, we found 
that hospitalization of HD patients varied from 35 to 88.2% 
[11–13, 17, 21, 32, 62, 82, 93, 109, 114, 116, 118, 120, 127, 
129, 133, 136–138, 144, 145, 150, 154]. with a percentage 
of patients requiring ICU admission of 2.6–70.5% [6, 13, 17, 
21, 32, 62, 109, 114, 116, 118, 119, 121, 125, 126, 129–134, 
136, 138, 143, 154]. A nonlinear correlation between the rate 
of hospitalization and ICU admission was noticed (Fig.  3S). 
Case-fatality rate of HD patients was heterogeneus, ranging 
from 0 to 47% [11–13, 15, 17, 19, 21, 32, 62, 82, 93, 108, 
109, 112–121, 123–138, 143–145, 147, 148, 150, 152, 154] 
and, as expected, outcome of patients who were admitted to 
ICU was poor with a mortality accounting for 42.8–100% of 
cases [13, 21, 82, 109, 114, 119, 125, 126, 129, 130, 154].
Discussion
Systematic scoping reviews are useful for examining 
emerging evidence when it is still unclear what other, more 
specific questions can be posed and valuably addressed 
by a more precise systematic review [8]. This is actu-
ally the case of COVID-19 pandemic. This systematic 
scoping review provides a synopsis of articles relating 
to COVID-19 and maintenance HD patients published in 
the time frame December 1, 2019–January 30, 2021. The 
areas investigated and analyzed by this scoping review 
range from the epidemiology to outcome and from clini-
cal presentation to management of in-centre HD patients 
with suspected or confirmed COVID-19. The main results 
of this study underline a worldwide broad-based consen-
sus for public health and clinical practice in the caring of 
HD patients (Table 3), a subset of the population severely 
affected by COVID-19. The nature of a semi‐closed com-
munity has probably enhanced the rapid spread of the 
infection within HD facilities.Except for the Canary Island 
where zero cases were found after a dialysis-wide universal 
screening [31], about 15% of the screened HD population 
contracted the infection (Fig. 1S). Spread of COVID-19 
was global and showed a highly heterogeneous distribu-
tion, changing significantly across the cities in the same 
country (China, Spain). A speculative explanation of this 
variable disease spreading pattern suggests that COVID-
19 pandemic manifested with local outbreaks rather than 
reflecting national trends [155].
As already said, the results of the epidemiology stud-
ies highlighted that asymptomatic patients accounted for 
about one-quarter of PCR-based screening of HD popula-
tion (Fig. 2S). The asymptomatic course of COVID-19, 
albeit favourable for the infected individuals, poses a threat 
for other patients, health workers as well as caregivers 
and drivers. Owing to the fact that COVID-19 can spread 
from asymptomatic carriers, surveillance and appropri-
ate management of suspected or confirmed COVID-19 
patients play a key role in the prevention of the infection. 
On this issue, a large amount of literature was published 
by the countries mostly hard-hit by the disease, namely, 
US, China, Italy, Brazil and UK [156].
Table 2  Timing of events in COVID-19 HD patients
Timing Days Statistical measure








Length of hospital stay 8–25.5 [11, 15, 21, 82, 109, 110, 115, 119, 120, 122, 
124, 130, 132, 153, 157]
16.2–22 [129, 131, 133]
(Median)
(Mean)
Length of ICU stay 13–15 [21, 119, 130]
6–19 [131, 133, 134]
(Median)
(Mean)
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Most of the current recommendations on the protection 
and control measures of HD patients derived from national 
guidelines, rapidly adapted to the dialysis setting to prevent 
the spread in the dialysis units. The analysis of the existing 
literature reported a common agreement on the cornerstones 
of the management of these patients. The principal clini-
cal management decisions for apparently healthy individu-
als included education, patient collaboration (e.g., timely 
communication of information on contacts or variation of 
the clinical status), hygiene (e.g., handwashing), use of PPE 
(e.g., mask), social distancing and screening (e.g., triage, 
testing). For suspected or confirmed COVID-19 patients, the 
core principle of the management was based essentially on 
the maintenance of isolation from other patients. There was 
indeed a consensus to dedicate an isolated room (if any) for 
suspected or confirmed COVID-19 patients until the reso-
lution of the infection. However, the map of the knowledge 
has brought to the light some divergences on the assess-
ment of patients that may reflect the inter-country differ-
ences in resource availability, healthcare delivery (private 
or public), and the possibilities to isolate efficiently patients 
in their facility (hospital-based or satellite dialysis unit). 
For instance, a different approach has been proposed for the 
diagnostic pathway of SARS-CoV-2 infection. Although a 
routine universal screening provides an optimal and effec-
tive control measure, many authors suggested performing 
RT-PCR nasopharyngeal swab only in symptomatic patients. 
This solution, less time-consuming and more cost-effective 
than routine RT-PCR nasopharyngeal swab, has the main 
drawback of leaving undetected asymptomatic or pre-symp-
tomatic patients.
Other differences in patient management concerned 
threshold of body temperature at triage, modality of COVID-
19 screening, distance between patients and timing of patient 
de-isolation. Whereas the former two issues are of easy 
resolution, discontinuing transmission-based precautions 
for HD patients relies on more complex underpinnings. The 
immune-suppressed HD patients may shed the virus longer 
than previously recognized [139]. Given the evolving recom-
mendations on the criteria for discontinuing isolation [157, 
158], may be prudential to consider HD patients as immuno-
compromised and await the resolution of nasal shedding 
before de-isolating these patients.
The outcome of the patients was heterogeneous and 
showed a case-fatality rate that in some cases was up to 47% 
[93]. Similar to the general population, exceptional higher 
Table 3  Areas of consensus and research bias of the selected studies
HD denotes hemodialysis; ICU, intensive care unit; PPE, personal protective equipment
Area Consensus Research bias/study limitation
Epidemiology of COVID-
19 within HD centers
Variability in the prevalence rate of COVID-19 among 
regions or countries
Screening of contacts and suspected COVID-19 cases 
reduces the spread of the virus within the dialysis 
center
Prevalence of COVID-19 influenced by the country's 
exposure to the pandemic risk and timing of the screen-
ing
Seroprevalence can be biased by the rate of seroconver-
sion and antibody waning
Use of different diagnostic tests
Management of HD patients Continuous education of patients is a priority within 
HD centers
Triage, hand hygiene, masking and social distanc-
ing are the cornerstone of COVID-19 containment 
measure
Expedited testing for COVID-19
Separate transportation is required for suspected or 
confirmed COVID-19 patients
An isolation room is required for testing and dialyzing 
suspected or confirmed COVID-19
Higher workload to dialyze COVID-19 HD patients in 
other rooms
Time without mask (drinking and eating) was mini-
mized
Recommendations are principally based on experts’ 
opinion
Lack of standardized management protocols to contain 
diffusion within dialysis centers
Inadequate supply of PPE and molecular tests for 
COVID-19
Shortage of disposable HD material and
reverse osmosis machines
No consensus on the minimum distance between patients 
in the waiting room and dialysis room, threshold body 
temperature and device to measure body temperature
Demographic and clinical 
characteristics of HD 
patients
Age of COVID-19 patients is heterogeneous
Variability in COVID-19 symptoms among HD 
patients
Prolonged shedding in COVID-19 patients
Age of incident HD patients varies among countries
Diagnosis of COVID-19 based on symptoms or chest 
imaging
Outcome Wide variability in the hospitalization, ICU access and 
case-fatality rate
Hospitalization rate is influenced by national policy on 
the hospitalization of COVID-19 patients
Mortality is influenced by bed capacity of the referring 
hospital
Criteria for ICU access varies among countries
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mortality was found in ICU, especially if the patients under-
went mechanical ventilation [159]. As already said, a nonlin-
ear correlation between the rate of hospitalization and ICU 
admission was noticed (Fig. 3S) and probably underscores 
a low ICU utilization among hospitalized HD patients. The 
causes of this event remain unanswered in the review. A 
lack of resource availability or a rapid worsening of clinical 
conditions in patients with multiple comorbidities probably 
discouraged from intensification of cures.
This review highlights the lack of information coming 
from low-income countries. Limited access to essential 
health services and SARS-CoV-2 testing probably justify 
poor reporting from these countries. A further alarming 
problem is that COVID-19 pandemic has disproportionately 
affected marginalized populations including patients with 
CKD [160, 161]. A study conducted across the US reported 
high seroprevalence of COVID-19 in younger patients, and 
patients living in poor and minority neighborhoods [162, 
163]. Considering COVID-19 could have even more dire 
consequences in developing countries, the paucity of data 
must not falsely reassure on the absence of human basic 
needs in these patients.
This review has some limitations. During the COVID-19 
pandemic, a consistent part (about one-third) of the pub-
lished literature was based on opinion papers and small 
case series. To generalize the message of our review we 
have excluded from the research abstracts, posters or con-
ference papers. Case reports or studies with a small sample 
size were selectively considered in case of a shortage of 
evidence. Conversely, we included (when present) knowl-
edge on pediatric HD patients. An enormous gap concerning 
principally the clinical course of the disease remains for this 
subset of the dialysis population. The milder disease course 
would justify the paucity of information. No data have been 
reported on home-dialysis patients because they carry a dif-
ferent profile of risk than in-centre dialysis patients.
In conclusion, this systematic scoping review provides an 
overview of the current knowledge on the impact of COVID-
19 on the frail world of HD patients. It underscores the need 
for extensive sharing of information between centres and 
within the healthcare community. A surrogate outcome of 
this review was the identification of knowledge gaps and 
areas for future research (Table 4), with the long-term goal 
of implementing the existing strategies of COVID-19 pre-
vention and providing a list of unmet clinical needs (safe 
transport, testing, shelter) for this vulnerable group of 
patients. Finally, the mapping of information often by sparse 
and fragmented literature should be a stimulus for perform-
ing systematic reviews and meta-analyses which will form 
the basis for evidence-based guidelines.
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Table 4  Controversies, 
knowledge gaps and areas 
for future research in the 
management of hemodialysis 
patients during COVID-19 
pandemic
Definition of asymptomatic, paucisymptomatic and symptomatic COVID-19 patients
Sensitivity and specificity of the available diagnostic tests (molecular, antigen, serologic)
Regulations concerning the containment measures on public transport
Standardization of the triage process
Minimum distance to prevent the spread of COVID-19 within HD center
Modality and timing of screening of COVID-19 in asymptomatic HD patients
Examinations required in HD patients with a new diagnosis of COVID-19
Role of preventive hospitalization in asymptomatic COVID-19 patients
Use of PPE during COVID-19 pandemic in infected and non-infected patients
Regulations concerning eating and drinking and presence of visitors during dialysis treatment
Criteria for discontinuation of isolation in COVID-19 patients
Use of dedicated dialysis machine/room/pathway for COVID-19 patients
Effects of ventilation on the spread of COVID-19 within the HD center
Prognostic factors for severity and mortality of COVID-19 patients
Anticoagulation for hemodialysis in COVID-19 patients
Dialytic dose in COVID-19 patients
Priority-setting for arteriovenous fistula creation
Risk of reinfection in HD patients
Defining cleaning and disinfection protocol of room and tools
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